Compare MANU & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MANU | RCUS |
|---|---|---|
| Founded | 1878 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | 601 |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 2012 | 2018 |
| Metric | MANU | RCUS |
|---|---|---|
| Price | $19.97 | $23.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $31.90 |
| AVG Volume (30 Days) | 256.0K | ★ 1.3M |
| Earning Date | 06-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.31 | $45.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.22 | $7.92 |
| 52 Week High | $20.12 | $28.72 |
| Indicator | MANU | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 65.05 | 42.16 |
| Support Level | $15.09 | $20.20 |
| Resistance Level | N/A | $24.33 |
| Average True Range (ATR) | 0.70 | 1.20 |
| MACD | 0.11 | -0.36 |
| Stochastic Oscillator | 95.16 | 12.71 |
Manchester United PLC operates as a professional football club with related activities, generating revenue prominently through commercial, broadcasting, and matchday segments. The commercial segment monetizes the various brands via sponsorships, retail, merchandising, apparel, and product licensing. Broadcasting revenue comes from television rights linked to football leagues and competitions, alongside content delivered through its dedicated TV channel all over the globe. Matchday income includes ticket sales, hospitality, merchandise, and services at its stadium. Manchester United is based in England. The company's operations and fan base extends to many countries, supporting a diversified revenue model based on brand engagement and football-related content.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.